anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled compound useful as an intermediate for producing a drug having inhibitory action on blood platelet aggregation and blood platelet adhesion ability industrially advantageously, by reacting 2-(2-thienyl)ethylemine with formaldehyde and then with hydrochloric acid to carry out ring formation. CONSTITUTION:2-(2-Thienyl)etylamine shown by formula I is reacted with formaldehyde to give a novel compound [e.g. 1,3,5-tris-(2-thienylethyl)-hexahydro-S- triazine, etc.] shown by formula II [R is 2-(2-thienyl)ethyl group shown by formula III. Then this compound is reacted with hydrochloric acid subjected to ring formation to give the aimed 4,5,6,7-tetrahydro-thieno-[3,2-C]pyridine shown by formula IV. This compound is subjected to 2-chloro-benzylation to give an inhibitor against blood platelet aggregation and blood platelet adhesion ability.
PURPOSE: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, characterized by intense lung infiltrations of immune cells (macrophages and monocytes). While existing studies have highlighted the crucial role of the competitive endogenous RNA (ceRNA) regulatory network in COPD development, the complexity and characteristics of the ceRNA network in monocytes remain unexplored.
METHODS: We downloaded messenger RNA (mRNA), microRNA (miRNA), and long noncoding RNA (lncRNA) microarray data from GSE146560, GSE102915, and GSE71220 in the Gene Expression Omnibus (GEO) database. This data was used to identify differentially expressed mRNAs (DEmRNAs), miRNAs (DEmiRNAs), and lncRNAs (DElncRNAs). Predicted miRNAs that bind to DElncRNAs were intersected with DEmiRNAs, forming a set of intersecting miRNAs. This set was then used to predict potential binding mRNAs, intersected with DEmRNAs, and underwent functional enrichment analysis using R software and the STRING database. The resulting triple regulatory network and hub genes were constructed using Cytoscape. Comparative Toxicomics Database (CTD) was utilized for disease correlation predictions, and ROC curve analysis assessed diagnostic accuracy.
RESULTS: Our study identified 5 lncRNAs, 4 miRNAs, and 149 mRNAs as differentially expressed. A lncRNA-miRNA-mRNA regulatory network was constructed, and hub genes were selected through hub analysis. Enrichment analysis highlighted terms related to cell movement and gene expression regulation. We established a LINC00482-has-miR-6088-PRRC2B ceRNA network with diagnostic relevance for COPD. ROC analysis demonstrated the diagnostic value of these genes. Moreover, a positive correlation between LINC00482 and PRRC2B expression was observed in COPD PBMCs. The CTD database indicated their involvement in inflammatory responses.
CONCLUSION: In summary, our study not only identified pivotal hub genes in peripheral blood mononuclear cells (PBMCs) of COPD but also constructed a ceRNA regulatory network. This contributes to understanding the pathophysiological processes of COPD through bioinformatics analysis, expanding our knowledge of COPD, and providing a foundation for potential diagnostic and therapeutic targets for COPD.
The present invention discloses a medicine for treating imbecillitas phenylpyruvica and a preparing method and use thereof, which has the aim to provide the medicine for treating imbecillitas phenylpyruvica. The medicine for treating imbecillitas phenylpyruvica has active ingredients which are normal bacteria of the intestinal tracts of a person and are used for expressing active phenylalanine deaminase. The normal bacteria of the intestinal tracts of a person are lactobacillus, or bacillus bifidus or galactococcus. The phenylalanine deaminase genes come from umbelliform flower department plants, or gramineous plants or rhodothece glutinis, wherein parsley, or paddy rice or the rhodotorula is preferable varieties. The medicine of the present invention has the advantages of simple manufacturing technique and low cost; the medicine can be accepted by most of patients. The medicine of the present invention can also be used as a catalyst by taking cinnamic acid and ammonia as productive raw materials to be produced into phenylalanine besides the treatment on imbecillitas phenylpyruvica.
This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
Glipizide-metformin hydrochloride tablets are capable of producing hypoglycemia; therefore, proper patient selection, dosing, and instructions are important to avoid potential hypoglycemic episodes. The risk of hypoglycemia is increased when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents or ethanol. Renal insufficiency may cause elevated drug levels of both glipizide and metformin hydrochloride. Hepatic insufficiency may increase drug levels of glipizide and may also diminish gluconeogenic capacity, both of which increase the risk of hypoglycemic reactions. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.
A kind of microparticle, made from multiple pharmaceutical excipients via process of emulsion and spray and dry method. The main components of the particles are as follows: A. Hydrophilic matrix: Sodium alginate, Gelatin. B. Lipophilic matrix: Iodized oil, (Cetyl alcohol and Stearyl alcohol, or one of them). Polycaprolactone. C. Surfactants: Polyoxyethylene (40) Stearate. D. The co-solvents: Sucrose, Sorbitol, Glycerol. E. Antioxidants: Sodium thiosulfate and Butylated hydroxytoluene, or one of them. F. Antibacterial agents: Propylparaben. G. Stabilizers: Cholesterol, Sodium Acetate. H. The cross-linking agents: Calcium chloride and Calcium lactate, or one of them. After spray and dry process and cross-linking, microparticle was made. It is then preserved in a dry state. Prior to use, the shape of its surface may recover by adding water into it. Soluble drugs can also be loaded at the same time. The microspheres can be used for embolization therapy, while the loaded drugs can enhance the treatment effects.
Background: The commercial availability of anamorelin, Japan's first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. Objective: We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. Methods: A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Results: Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Conclusion: Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin's therapeutic benefits.
Hospitalization for medical illness is a unique and missed opportunity for intervention for alcohol use disorders (AUDs). Referrals can help link patients from hospitals to alcohol treatment. But most patients return to heavy drinking after hospital discharge and do not follow-up with alcohol treatment, risking hospital readmission. Pharmacotherapy has efficacy for AUD, but adherence to these medications is poor. Furthermore, these medications are rarely prescribed in general medical settings, during or after hospitalization. Beginning treatment for AUD during a hospitalization for medical illness could broaden the reach of effective treatment and is likely to be more effective than delaying treatment until a specialist visit or treatment program entry. Hospital discharge is a time of both risk (i.e., for drinking and non-adherence to medical care) and opportunity (i.e., to begin alcohol treatment and complete medical treatments). Interventions that work quickly and improve adherence could improve medical and alcohol-related outcomes.

Oral naltrexone (PO-NTX), and the more-costly-per-dose long-acting injectable extended release naltrexone (XR-NTX) are Food and Drug Administration (FDA)-approved efficacious treatments for AUD. The XR-NTX half-life is 5-10 days and is dosed monthly, whereas the PO-NTX half-life is 13 hours and is dosed daily. The longer half-life of XR-NTX translates into patients receiving effective pharmacotherapy for a longer time without having to adhere to a daily dose. Thus, although more costly per dose, greater effectiveness could mean overall reduced costs of care (including alcohol-related health consequences and healthcare utilization). Despite potential differences in costs and patient preferences, PO-NTX and XR-NTX have not been directly compared in a randomized controlled trial (RCT), they have not been studied as treatments at medical hospital discharge, and their effectiveness in real world practice settings compared with standard care is unknown.

This trial is significant because it will address the clinically relevant comparative effectiveness question and lead to greater adoption of the most effective and cost-effective approach for treating AUD with pharmacotherapy in general hospitals.
This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
ECT is a safe and effective modern treatment for severe depression and other psychiatric conditions. An estimated 100,000 treatments occur per year in the United States. ECT's most bothersome adverse effect is memory loss, with all patients receiving ECT experiencing some degree of short-term cognitive impairment. At present there are no known effective pharmacologic treatments to prevent or improve ECT-induced cognitive dysfunction. Preliminary research has shown the herbal preparation GB aids cognitive function and memory in both patients with dementia and in normal volunteers. This study will investigate the utility and safety of GB to minimize the cognitive impairment typically associated with ECT.

Participants in this study will be randomly assigned to receive either twice-daily GB or placebo. Participants will begin taking GB or placebo as soon as consent is obtained and baseline testing is completed in order to reach steady-state plasma levels of GB prior to ECT. Patients will undergo cognitive testing at specified intervals following ECT. The final study visit will occur one week after a participant's final ECT treatment.
The present invention involves the reaction of a CD4 immuno-conjugate with a sample of patient whole blood. The CD4 immuno-conjugate consists of one or more antibodies with specificity for the CD4 surface receptor coupled to a signal moiety, or “label”, that is detectable by a flow cytometer. Such labels may generate a signal by such means as fluorescence properties, light scatter properties, electronic properties, or magnetic properties. The CD4 immuno-conjugate binds to both the CD4 positive lymphocytes (Helper T cells) and all monocytes. Differential detection means are employed to count immuno-conjugate labeled Helper T cells. The present invention distinguishes itself by simultaneously measuring the signal level from monocytes as a means to verify sufficient activity of the anti-CD4 antibody.
PROBLEM TO BE SOLVED: To obtain a stable ointment preparation for rectal administration readily and rapidly absorbed from rectum by controlling the viscosity of an antipyretic, analgesic and antiphlogistic agent to a specific range. SOLUTION: This ointment preparation for rectal administration contains an antipyretic, analgesic and antiphlogistic agent as an active ingredient and controls the viscosity in the range of 1,000 to 10,000 mPa.s (at 25 deg.C). The viscosity of the preparation is controllable by a base used or its amount used, use, of an additive such as a thickener, etc. White vaseline (in an amount of 25-90 wt.%) or a middle-chain fatty acid triglyceride (in an amount of 5-70 wt.%) is preferably used as the base. A thickener (preferably lightweight anhydrous silicic acid) is further preferably added thereto. Dichlofenac sodium is preferably used as the antipyretic, analgesic and antiphlogistic agent. The agent in this case is formulated in an amount of 0.01-30.0 wt.% based on the ointment preparation.
Various methods and systems are provided for capture and transmission of images to a secure repository. In one example, among others, a method includes capturing an image of a document as an image file using a mobile device, adding metadata to the image file, and securely transmitting the image file to a server. The image file can be stored in a secure repository. In another example, a mobile device includes a secure transfer application that causes the mobile device to capture an image as an image file, add metadata to the image file, and transmit the image file to a server via a secure connection. The server may store the image file in a secure repository. In another example, a non-transitory computer-readable medium includes a program that captures an image, adds metadata to the image file, and transmits the image file securely to a server.
A method and system for generating an optimal audio stimulus for achieving a target brain state value for a brain state. The method and system can be used to generate one or more brain state models which can decode brain activity signals to predict brain state values. The brain state models can be applied to brain activity signals captured while users are performing tasks with an audio stimulus. Audio features of the audio stimulus can be extracted. An audio-brain model can be trained on the predicted brain state values and the audio features. From the trained audio-brain model, the optimal audio stimulus can be generated.
Peripheral artery disease (PAD) affects 8 to 12 million individuals in the United States and is also prevalent in Europe and Asia. A regional pilot study of community screening for PAD demonstrated that patient awareness of a PAD diagnosis was low, and was associated with atherosclerosis risk factors, antiplatelet therapy, and claudication treatment intensity. PAD has not emerged as a focus of public health efforts to improve quality of life, nor to decrease the associated cardiovascular ischemic risk. Smoking, diabetes, and age are the strongest risk factors for PAD. Smokers have a 2 to 6-fold increased likelihood of having PAD, and the risk of PAD increases in a dose-dependent manner with the duration and amount of smoking. Diabetes confers a 2 to 4-fold increased risk of having PAD. The prevalence of PAD increases as a function of age. Criqui et al showed that the prevalence of PAD in individuals under 60 years of age was about 2.5%, whereas the prevalence increased to over 20% in individuals over 75 years of age.

A study in smokers and diabetics 50 years of age or older, and in all those 70 years of age or older, identified in an outpatient, primary care clinic setting has shown that the prevalence is 29%. About half of the cases found were newly-identified PAD patients. Further, while 83% of those with a prior diagnosis of PAD were aware of their condition, only 49% of the primary-care physicians were aware that their patients had a diagnosis of PAD. Another study examined internal medicine physicians' approaches to PAD and found that only 37% reported taking histories for claudication, and only 26% evaluated the foot for ulcers.

PAD is as prevalent in women as in men. When symptomatic, PAD causes limb discomfort, tiredness, heaviness, cramping, or pain brought on by exertion and relieved by rest (i.e., intermittent claudication) and reduces functional capacity and quality of life. Classic claudication is only noted by 10-30% of patients and atypical leg discomfort occurs in 20-40%. Up to 50% of patients are asymptomatic. PAD1 is an in vitro diagnostic that provides a PAD1 score derived from multiple biomarkers in human plasma, serum, or whole blood, which predicts a low or high probability of the presence of PAD in patients at risk for PAD. A positive PAD1 score(above the cutoff), indicating a higher risk for PAD than expected in the general population, would then guide the physician to more aggressively determine the presence of PAD.

The preliminary studies have shown an association of four proposed biomarkers with ABI, and have demonstrated the construction of a PAD risk algorithm. This study is powered to test each of the four biomarkers and their interactions and develop the PAD1 risk score in the intended use population.
In the setting of pronounced inflammation, changes in the epithelium may overlap with neoplasia, often rendering it impossible to establish a diagnosis with certainty in daily clinical practice. Here, we discuss the underlying molecular mechanisms driving tissue response during persistent inflammatory signaling along with the potential association with cancer in the gastrointestinal tract, pancreas, extrahepatic bile ducts, and liver. We highlight the histopathological challenges encountered in the diagnosis of chronic inflammation in routine practice and pinpoint tissue-based biomarkers that could complement morphology to differentiate reactive from dysplastic or cancerous lesions. We refer to the advantages and limitations of existing biomarkers employing immunohistochemistry and point to promising new markers, including the generation of novel antibodies targeting mutant proteins, miRNAs, and array assays. Advancements in experimental models, including mouse and 3D models, have improved our understanding of tissue response. The integration of digital pathology along with artificial intelligence may also complement routine visual inspections. Navigating through tissue responses in various chronic inflammatory contexts will help us develop novel and reliable biomarkers that will improve diagnostic decisions and ultimately patient treatment.
Transplant recipients are particularly vulnerable to medication errors because of the large number of chronic drugs needed to prevent rejection and treat comorbidities. Compliance failures directly compromise patient safety through acute immunologic events and premature graft loss. For society, the loss of invested fiscal and organic (organs) resources is catastrophic. As the unique constant in the chain of people who provide, modify and consume prescription medications, health information technology should be focused on empowering the patient to prevent medication errors. Our principal clinical hypothesis is that HIT can be proven to improve patient safety by minimizing medication errors. Specific aims address the creation of new knowledge and evidence ( in a renal transplant population) of benefits of widely applicable HIT tools. Web enabled education of two groups, new (\<6 months) and established (\> 6 months), kidney transplant recipients is proposed.
This study is a matched case-control study of risk factors for human infection with avian influenza A (H5N1) virus in China. The primary study objective is to determine the risk factors for avian influenza A (H5N1) virus infection in humans, in China, whether or not the subject was symptomatic. The confirmed case-patients and confirmed antibody positive avian influenza A (H5N1) persons (asymptomatic or sub-clinical) identified by the previously done National Surveillance Program will be included in this study as cases. Controls will be identified from population registries in villages with rural cases and in the adjacent apartment buildings of the urban cases' residences. If the National Surveillance Program identifies healthcare workers infected with avian influenza A (H5N1) virus, healthcare workers in the same department of the healthcare facilities in which the cases worked will also be included as controls. A matched case-control study will be conducted with a ratio of 4 controls per 1 case. Cases and controls who meet the eligibility criteria will be consented and enrolled in the study. After enrollment a questionnaire will be administered to obtain information on demographic characteristics, underlying diseases, daily activities, shopping habits, poultry raising in the backyard, poultry vaccination, exposure to sick/dead poultry or healthy appearing poultry, visits to places where live poultry were kept (e.g., poultry stalls, retail markets, wholesale markets or poultry farms) in the week before illness, eating habits, food preparation activities related to poultry, children's activities such as playing with poultry and swimming in water with water fowl, exposure to other animals including wild birds, and exposure to other humans with respiratory illnesses or confirmed H5N1 case-patients. Survived cases, individuals whose specimen H5N1 tested positive in previous National Surveillance Program and controls will be asked to provide a blood sample to determine whether they have antibodies to H5N1. New confirmed cases and controls will be asked to donate a blood sample for H5N1 antibody testing. Any control that tests positive will become a case and additional controls will be identified. All samples will be tested for H5N1 antibodies with hemagglutination inhibition (using horse red blood cells) and microneutralization assay. If all negative, the individual will be considered sero-negative; if all positive, the individual will be considered sero-positive for the purposes of this study; if results from hemagglutination inhibition (HI) and microneutralization (MN) assays are discordant, the MN result will be considered the final result (negative or positive). Appropriate antigens for the assays will be selected based on the antigenic characteristics of the virus circulating in the region at the time of sample collection. HI and MN assays will be performed according to accepted SOPs. The study will be completed within one year.